After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
We are very excited to launch our new website! Please take a few moments to click around and explore...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...